A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease
This is multicentre, proof of concept, randomized, double-blind, parallel-group, placebo-control study in 40 Parkinson's Disease (PD) patients. Patients will be randomized in 2 groups receiving Bumetanide or placebo for 4 months:
Group 1 (20 PD patients): bumetanide
Group 2 (20 PD patients): placebo intake identically to group 1.
100 Clinical Results associated with B&A Therapeutics
0 Patents (Medical) associated with B&A Therapeutics
100 Deals associated with B&A Therapeutics
100 Translational Medicine associated with B&A Therapeutics